摘要
Abstract
Objective To evaluate the safety and efficacy of Sorafenib combined with hepatic artery chemoembolization (TACE) in the treatment of hepatocellular carcinoma with hepatic arteriovenous shunt. Method 96 cases of hepatocellular carcinoma with hepatic arteriovenous shunt patients treated in our hospital from January 2013 to January 2015 were selected as the research objects. They were randomly divided into observation group and control group, 48 cases in each group, all patients were treated with TACE. Patients in observation group were treated with Sorafenib orally, and persisted until they could not be tolerated. The liver function, serum alpha fetoprotein (AFP) and vascular endothelial growth factor (VEGF) levels changes, clinical efficacy, adverse reactions and survival time were compared between the two groups before and 8 weeks after treatment.Result 8 weeks after treatment, alanine aminotransferase and total bilirubin in the two groups were significantly higher than before treatment (P<0.05), albumin, AFP and VEGF levels were lower than before treatment (P<0.05), AFP and VEGF levels of observation group were significantly lower than control group (P<0.05). There were no significant differences of clinical total effective rates, clinical benefit rates and incidence of adverse reactions during treatment between the two groups (P>0.05). The overall survival and progression free survival time of observation group were longer than that of control group (P<0.05). Conclusion Single TACE and Sorafenib combined with TACE in the treatment of hepatocellular carcinoma with hepatic arteriovenous shunt have similar short-term efficacy, combination therapy has a more positive effect on prolonging survival time of the patients, and the security is good.关键词
索拉非尼/肝动脉化疗栓塞/肝癌并肝动-静脉分流/疗效/安全性Key words
Sorafenib/Transcatheter arterial chemoembolization/Hepatocellular carcinoma with hepatic arteriovenous shunt/Efficacy/Safety
